SLC5A2 and diabetic kidney disease: Data from randomized controlled trials (CREDENCE, SCORED, DAPA‐CKD, and EMPA‐KIDNEY) demonstrate improvements in cardiorenal outcomes following SGLT2‐inhibitor treatment in diabetic kidney disease (and non‐diabetic CKD) [72, 73, 74, 75, 76, 77].